stockportfolio.pro
Stocks / EPRX vs SGMT
EPRX vs SGMT
Eupraxia Pharmaceuticals Inc. and Sagimet Biosciences Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Eupraxia Pharmaceuticals Inc. (EPRX) | Sagimet Biosciences Inc. (SGMT) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-38.58M | $-51.04M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | -47.0% | -45.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | — |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open EPRX — free Open SGMT — freeFrequently asked questions
Which is bigger, EPRX or SGMT?
Sagimet Biosciences Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, EPRX or SGMT?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.